Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053342 | 1.00 | TSHR (0.38) | TSHRMAPK1MAPTALDH1A1PKM | |
| SCHEMBL31531593 | 0.88 | TSHR (0.47) | TSHRMAPK1MAPTALDH1A1PKM | |
| SCHEMBL15053385 | 0.88 | TSHR (0.47) | TSHRMAPK1MAPTALDH1A1PKM | |
| SCHEMBL15053383 | 0.88 | TSHR (0.47) | TSHRMAPK1MAPTALDH1A1PKM | |
| SCHEMBL15053052 | 0.85 | CCR2 (0.41) | TSHRMAPK1MAPTALDH1A1PKM | |
| SCHEMBL15053054 | 0.85 | CCR2 (0.41) | TSHRMAPK1MAPTALDH1A1PKM | |
| SCHEMBL14992158 | 0.84 | EPAS1 (0.47) | MAPK1MAPTALDH1A1LMNAPDE7A | |
| SCHEMBL14995049 | 0.79 | MEN1 (0.38) | MAPK1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL14995048 | 0.79 | MEN1 (0.38) | MAPK1MAPTALDH1A1LMNAHPGD | |
| SCHEMBL14993373 | 0.79 | TSHR (0.47) | TSHRMAPK1MAPTALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9790204-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2785710-B1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2785710-B1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185756-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9150550-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140121195-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20130165423-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165423-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TSHR 2717/4885MAPK1 2876/4885MAPT 3395/4885 |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TSHR 2717/4885MAPK1 2876/4885MAPT 3395/4885 |
| US-20160185756-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TSHR 2717/4885MAPK1 2876/4885MAPT 3395/4885 |
| US-20140121195-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TSHR 2717/4885MAPK1 2876/4885MAPT 3395/4885 |
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CCR4, CCR1, CCR3 | TSHR 2717/4885MAPK1 2876/4885MAPT 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.